New Gram-positive agents in nosocomial infection

Current Opinion in Infectious Diseases

Volumn 13, Issue 6, 2000, Pages 593-598

  Patterson, Jan E ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; CEFAZOLIN; CYCLOSPORIN A; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; MIDAZOLAM; NIFEDIPINE; OXACILLIN; OXAZOLIDINE DERIVATIVE; PRISTINAMYCIN; STREPTOGRAMIN; TERFENADINE; VANCOMYCIN;

ARTHRALGIA; BACTEREMIA; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; DIARRHEA; DRUG ELIMINATION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; HEADACHE; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYALGIA; PNEUMONIA; REVIEW; SKIN INFECTION; SUPERINFECTION; THROMBOCYTOPENIA;

EID: 0033673071     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200012000-00003     Document Type: Review

References (32)

1. Bacterial pathogens isolated from patients with blood stream infections: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program
2. National Nosocomial Infection Surveillance System. Nosocomial vancomycin resistant enterococci (VRE) in the United States, 1989-1995: The first 1000 isolates
3. Vancomycin-resistant enterococci
4. Methicillin-resistant Staphylococcus aureus as a community organism
5. Staphylococcus aureus with reduced susceptibility to vancomycin: Illinois 1999
6. Quinupristin/dalfopristin: A new therapeutic option for serious hospital-acquired infections
7. Quinupristin/dalfopristin. A review of its use in the management of serious Gram-positive infections
8. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium
9. Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium
10. Treatment of hospitalized patients with complicated Gram-positive skin and skin-structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin
11. Treatment of Gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin
12. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia
13. Safety and tolerability of quinupristin/ dalfopristin: Administration guidelines
14. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus fecium bacteremia
15. Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy
16. Quinupristin/dalfopristin
17. In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci
18. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae
19. Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom
20. Oxazolidinones. A review
21. A novel antimicrobial agent joins the battle against resistant bacteria
22. Linezolid
23. In vitro activity of linezolid combined with other antibacterial agents
24. Linezolid. A synthetic oxazolidinone antimicrobial for treatment of serious gram-positive infections
25. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections
26. Outcomes with linezolid from an ongoing compassionate use trial of patients with significant, resistant, gram positive infections
27. Linezolid (Zyvox)
28. Safety and efficacy of linezolid in eradication of nasal Staphylococcus aureus
29. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid